Scandinavian ChemoTech AB Series B (CMOTEC-B) - Net Assets
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has net assets worth Skr1.64 Million SEK (≈ $176.17K USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr11.11 Million ≈ $1.20 Million USD) and total liabilities (Skr9.47 Million ≈ $1.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CMOTEC-B goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.64 Million |
| % of Total Assets | 14.74% |
| Annual Growth Rate | 46.92% |
| 5-Year Change | -86.68% |
| 10-Year Change | -78.15% |
| Growth Volatility | 651.1 |
Scandinavian ChemoTech AB Series B - Net Assets Trend (2014–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's net assets have evolved over time, based on quarterly financial data. See Scandinavian ChemoTech AB Series B defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Scandinavian ChemoTech AB Series B (2014–2025)
The table below shows the annual net assets of Scandinavian ChemoTech AB Series B from 2014 to 2025. For live valuation and market cap data, see Scandinavian ChemoTech AB Series B (CMOTEC-B) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr3.19 Million ≈ $342.86K |
-46.72% |
| 2024-12-31 | Skr5.98 Million ≈ $643.54K |
-45.79% |
| 2023-12-31 | Skr11.03 Million ≈ $1.19 Million |
-21.16% |
| 2022-12-31 | Skr13.99 Million ≈ $1.51 Million |
-41.50% |
| 2021-12-31 | Skr23.92 Million ≈ $2.57 Million |
+158.95% |
| 2020-12-31 | Skr9.24 Million ≈ $993.94K |
-5.07% |
| 2019-12-31 | Skr9.73 Million ≈ $1.05 Million |
-52.53% |
| 2018-12-31 | Skr20.50 Million ≈ $2.21 Million |
+99.23% |
| 2017-12-31 | Skr10.29 Million ≈ $1.11 Million |
-29.46% |
| 2016-12-31 | Skr14.58 Million ≈ $1.57 Million |
+1578.88% |
| 2015-12-31 | Skr868.64K ≈ $93.48K |
+1777.36% |
| 2014-12-31 | Skr46.27K ≈ $4.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Scandinavian ChemoTech AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 805040600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr12.73 Million | 399.47% |
| Total Equity | Skr3.19 Million | 100.00% |
Scandinavian ChemoTech AB Series B Competitors by Market Cap
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REFINED METALS CORP. O.N.
F:CWA0
|
$9.31 Million |
|
Larq SA
WAR:LRQ
|
$9.31 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
$9.32 Million |
|
Lohilo Foods AB
ST:LOHILO
|
$9.32 Million |
|
Kordellos Ch. Bros S.A
AT:KORDE
|
$9.30 Million |
|
First Media Tbk
JK:KBLV
|
$9.29 Million |
|
IQ Group Holdings Bhd
KLSE:5107
|
$9.28 Million |
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
$9.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandinavian ChemoTech AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,980,000 to 3,186,000, a change of -2,794,000 (-46.7%).
- Net loss of 8,055,999 reduced equity.
- New share issuances of 5,088,000 increased equity.
- Other comprehensive income increased equity by 108,869,000.
- Other factors decreased equity by 108,695,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.06 Million | -252.86% |
| Share Issuances | Skr5.09 Million | +159.7% |
| Other Comprehensive Income | Skr108.87 Million | +3417.11% |
| Other Changes | Skr-108.70 Million | -3411.64% |
| Total Change | Skr- | -46.72% |
Book Value vs Market Value Analysis
This analysis compares Scandinavian ChemoTech AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 139.09x to 27.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.03 | Skr3.63 | x |
| 2014-12-31 | Skr0.03 | Skr3.63 | x |
| 2015-12-31 | Skr0.76 | Skr3.63 | x |
| 2016-12-31 | Skr9.98 | Skr3.63 | x |
| 2017-12-31 | Skr7.03 | Skr3.63 | x |
| 2018-12-31 | Skr6.28 | Skr3.63 | x |
| 2019-12-31 | Skr2.37 | Skr3.63 | x |
| 2020-12-31 | Skr1.88 | Skr3.63 | x |
| 2021-12-31 | Skr2.76 | Skr3.63 | x |
| 2022-12-31 | Skr1.40 | Skr3.63 | x |
| 2023-12-31 | Skr0.79 | Skr3.63 | x |
| 2024-12-31 | Skr0.26 | Skr3.63 | x |
| 2025-12-31 | Skr0.13 | Skr3.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandinavian ChemoTech AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -252.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.58%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 4.14x
- Recent ROE (-252.86%) is below the historical average (-118.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -16.80% | 0.00% | 0.00x | 1.00x | Skr-11.90K |
| 2014 | -60.81% | 0.00% | 0.00x | 1.42x | Skr-32.76K |
| 2015 | -135.94% | -8498.88% | 0.00x | 7.66x | Skr-1.27 Million |
| 2016 | -55.81% | -390.48% | 0.12x | 1.15x | Skr-9.60 Million |
| 2017 | -80.99% | -30582.56% | 0.00x | 1.25x | Skr-9.36 Million |
| 2018 | -23.41% | -856.61% | 0.02x | 1.11x | Skr-6.85 Million |
| 2019 | -129.36% | -2263.49% | 0.03x | 1.80x | Skr-13.56 Million |
| 2020 | -126.29% | -8903.82% | 0.01x | 1.73x | Skr-12.59 Million |
| 2021 | -74.19% | -36210.20% | 0.00x | 1.08x | Skr-20.13 Million |
| 2022 | -162.56% | -4808.88% | 0.02x | 1.55x | Skr-24.15 Million |
| 2023 | -191.20% | -747.38% | 0.19x | 1.35x | Skr-22.19 Million |
| 2024 | -229.38% | -208.91% | 0.49x | 2.24x | Skr-14.31 Million |
| 2025 | -252.86% | -65.58% | 0.93x | 4.14x | Skr-8.37 Million |
Industry Comparison
This section compares Scandinavian ChemoTech AB Series B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $192,211,000
- Average return on equity (ROE) among peers: -57.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandinavian ChemoTech AB Series B (CMOTEC-B) | Skr1.64 Million | -16.80% | 5.78x | $9.30 Million |
| 2cureX AB (2CUREX) | $28.08 Million | -28.26% | 0.35x | $5.16 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $41.03 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $9.52 Million |
| Active Biotech AB (ACTI) | $182.56 Million | -32.64% | 1.26x | $103.60 Million |
| Alzinova AB (ALZ) | $123.82 Million | -16.60% | 0.08x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $46.62 Million |
| Annexin Pharmaceuticals AB (ANNX) | $24.44 Million | -126.54% | 0.26x | $9.23 Million |
| Alligator Bioscience AB (ATORX) | $10.91 Million | 0.00% | 0.59x | $11.36 Million |
| BioInvent International AB (BINV) | $394.25 Million | 11.71% | 0.13x | $163.58 Million |
| BioArctic AB (publ) (BIOA-B) | $1.02 Billion | 37.50% | 0.37x | $2.39 Billion |
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more